Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25134616 | 0.89 | AGTR2 (0.57) | NR1H2NR1H3AGTR2GPR119ALDH1A1 | |
| SCHEMBL25606205 | 0.88 | NR1H2 (0.63) | NR1H2NR1H3GPR119ALDH1A1LMNA | |
| SCHEMBL38663567 | 0.86 | NR1H2 (0.48) | NR1H2NR1H3GPR119ALDH1A1LMNA | |
| SCHEMBL17749010 | 0.85 | NR1H2 (0.49) | NR1H2NR1H3AGTR2GPR119ALDH1A1 | |
| SCHEMBL38661611 | 0.85 | NR1H2 (0.46) | NR1H2NR1H3GPR119ALDH1A1LMNA | |
| SCHEMBL38661629 | 0.82 | NR1H2 (0.48) | NR1H2NR1H3GPR119MAP4K4USP30 | |
| SCHEMBL38662321 | 0.82 | NR1H2 (0.46) | NR1H2NR1H3GPR119MAP4K4USP30 | |
| SCHEMBL25220311 | 0.80 | GPR119 (0.57) | NR1H2NR1H3GPR119ALDH1A1MAP4K4 | |
| SCHEMBL25251258 | 0.79 | NR1H2 (0.41) | NR1H2NR1H3LMNAMAP4K4USP30 | |
| SCHEMBL29252894 | 0.79 | NR1H2 (0.41) | NR1H2NR1H3LMNAMAP4K4USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4405334-B1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-02-12 | — | — | EP | disclosed |
| US-20250002460-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-01-02 | — | — | US | disclosed |
| EP-4405334-A1 | SORTILIN INHIBITORS | Sortina Pharma AB (SE) | 2024-07-31 | — | — | EP | disclosed |
| CN-118317947-A | Sortilin inhibitors | 索蒂纳制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023101595-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023101595-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002460-A1 | SORTILIN INHIBITORS | SORT1, GRN, SCARB1 | NR1H2 1056/4885NR1H3 1185/4885AGTR2 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.